Skip to main content

Table 3 Trends of vaccine uptake in patients with and without systemic lupus erythematosus (SLE) in the Lupus Midwest Network cohort between 2015 and 2020

From: Utilization of preventive services in a systemic lupus erythematosus population-based cohort: a Lupus Midwest Network (LUMEN) study

 

Cumulative incidence, % (95% CI)

 

Immunizationa

1 year

2 years

3 years

5 years

 
 

SLE

Non-SLE

SLE

Non-SLE

SLE

Non-SLE

SLE

Non-SLE

HRb (95% CI)

Influenza

60.6 (56.2–65.3)

51.6 (47.1–56.6)

69.4 (65.2–73.8)

60.1 (55.6–65.0)

73.0 (68.9–77.3)

63.5 (59.0–68.3)

75.3 (71.3–79.5)

69.8 (65.4–74.6)

1.31 (1.12–1.54)

Pneumococcal disease

6.9 (3.8–12.5)

4.1 (2.3–7.4)

12.5 (8.1–19.2)

9.2 (6.3–13.5)

25.5 (19.2–33.8)

12.8 (9.3–17.6)

33.9 (26.8–42.8)

18.2 (13.9–23.7)

2.06 (1.38–3.09)

Herpes zosterc

11.4 (7.9–16.5)

7.5 (4.8–11.9)

25.8 (20.6–32.4)

22.3 (17.3–28.6)

–

–

–

–

1.17 (0.81–1.69)

  1. CI confidence interval, HR hazard ratio
  2. aSeasonal influenza immunization was recommended every year [40]. Pneumococcal immunization was evaluated with the 13-valent pneumococcal conjugate vaccine (PCV13) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23); the recommended revaccination for the PPSV 23 was 5 years after the first dose, up to 2 shots in lifetime, and there was not a revaccination recommendation for the PCV13 [41, 42]. Zoster vaccination was evaluated with a single dose of the recombinant zoster vaccine; a second dose should be given 2–6 months later, up to 2 shots in lifetime [43, 44]
  3. bCox proportional hazards models with adjustment for age, sex, and race at 5 or 2 years, as correspond. The number of patients at risk on each timepoint is shown in supplemental table 6
  4. cAfter recombinant zoster vaccine became available (January 1, 2018)
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us